The French President is facing an uphill battle to get France vaccinated quickly after delays in delivery and his startling comments on the AstraZeneca jab. In January, Mr Macron claimed that the Oxford-AstraZeneca vaccine was "quasi-ineffective" for over-65s, hours before it was approved by regulators for use on all adults in the EU. This week, France approved the jab, but the President's previous comments could prove detrimental to the rollout. Only 273,000 AstraZeneca doses have been administered in France out of 1.7 million received as of the end of February, according to Paris health ministry figures.
Mr Macron's comments came before another big mistake by his government, as politicians in France fumed at the country's failure to quickly secure Valneva jabs.
Christelle Morancais, regional council president for the Loire region, told the Telegraph last month: “What happened in the UK? They rolled out the red carpet for this company.
“They helped with financing, installation. They’ve done everything to make it happened and we haven’t been able to do that.”
Frank Grimaud, chief executive at Valneva, added: “We have a manufacturing factory in Scotland nearby Edinburgh and it was considered very quickly by the UK as a very important asset.Insurance Loans Mortgage Attorney Credit Lawyer
“So that is why it was in a way natural to find very quickly an agreement to develop an inactivated vaccine and to develop our manufacturing capacity.”
Emmanuel Macron news: Macron has come under fire for the vaccine rollout in France (Image: getty)
Emmanuel Macron news: Merkel and Macron have U-turned on the AZ vaccine (Image: getty)
Valneva – a Franco-Austrian company – has sold 100 million jabs to the UK, costing £1.2billion.
Britain will begin receiving its doses in October, while France and the EU may have to wait until 2022.
Ms Morancais added: “It is vital that the state proves it has much more agility and reactivity when it comes to supporting and defending our companies at the forefront of fighting the virus.”
"France has missed the chance of its own Covid